Nathaniel Brooks Horwitz is a GentiBio Board Observer and Principal at RA Capital Management, a healthcare and life sciences investment firm. He has served as a Director or Observer on the boards of several RA Capital portfolio companies, including Quench Bio, Eliem Therapeutics, Clear Creek Bio, and multiple stealth-mode ventures. He was previously CEO of Nivien Therapeutics. His writing on biotech and other subjects has been published by The Washington Post, The New York Times, The Atlantic, The Boston Globe, and The Financial Review. Horwitz received an A.B. in Molecular and Cellular Biology from Harvard University.
Nathaniel Brooks Horwitz
Venture Partner, RA Capital Management, Board Observer